natgillin/translations-raw huggingface dataset:
fits without temperature or due to high temperature (fever)
napadi krčev brez zvišane telesne temperature ali zaradi zvišane telesne temperature (vročine)
fits, change in mental status or alertness, sleepiness, difficulty with your balance, dizziness, confusion, forgetfulness, difficulty concentrating, tingling sensation, “pins and needles”, difficulty speaking or understanding language, shaking, stroke.
krči/napadi, spremembe duševnega stanja ali budnosti, zaspanost, težave z ravnotežjem, omotica, zmedenost, pozabljivost, težave z zbranostjo, zbadanje, mravljinčenje, težave z govorom ali razumevanjem govorice, tresenje, kap
Fits, disturbances in consciousness, tingling and numbness (sometimes painful) in the hands and feet, dizziness, impaired writing ability, nervous system disorders
epileptični napadi, motnje zavesti, mravljinčenje in odrevenelost (včasih boleča) v rokah in nogah, omotica, zmanjšana sposobnost za pisanje, bolezni živčevja,
fits, disturbances in consciousness, tingling and numbness (sometimes painful) in the hands and feet, dizziness, impaired writing ability, nervous system disorders
epileptični napadi, motnje zavesti, zbadanje in odrevenelost (včasih boleče) v rokah in nogah, omotica, zmanjšana sposobnost za pisanje, bolezni živčevja
fits, fainting, mini strokes (including weakness of the face or an inability to speak), reduced responsiveness (which may include a comatose state), trembling, sleepiness
krči, omedlevica, majhne kapi (vključno z oslabelostjo obraza ali nezmožnostjo govoriti), manjša odzivnost (ki lahko vključuje komatozna stanja), tresavica, zaspanost
fits, feeling confused, seeing or hearing things that are not real (hallucinations), feeling excited, movements that you cannot control, a tendency to wonder away, feeling dizzy, headache, feeling restless, lacking energy
epileptični napadi, občutek zmedenosti, vidno in slušno zaznavanje stvari, ki niso resnične (halucinacije), občutek vzburjenja, nenadzorovani gibi, nagnjenost k brezciljnem beganju, omotica, glavobol, nemir, pomanjkanje energije,
Five (5) patients with MDS/MPD associated with PDGFR gene re-arrangements were reported in 4 publications.
4 publikacijah so objavljeni podatki petih (5) bolnikov z MDS/MPD s preureditvijo gena za PDGFR.
Five (5) patients with MDS/MPD associated with PDGFR gene re-arrangements were reported in 4 publications.
V publikacijah so objavljeni podatki petih (5) bolnikov z MDS/MPD s preureditvijo gena za PDGFR.
Five (5)patients with DFSP and PDGFR gene re-arrangements were reported in 3publications.
V 3 publikacijah so objavljeni podatki petih (5) bolnikov z DFSP s preureditvijo gena za PDGFR.
Five -year data from a long-term open-label uncontrolled study indicate that an estimated 77.9% [95% CI (71.9%, 83.8%)] of all the subjects who initially received treatment became clinically clear and remained clear at 60 months.
Ocenjujejo, da so pri 77,9% [ (95% interval zaupanja (IZ) 71,9; 83,8%)] bolnikov, ki so prejeli zdravilo na začetku, klinični znaki bolezni izginili in se 60 mesecev niso ponovno pojavili.
five 25 mg tablets twice daily or
pet 25 mg tablet dvakrat na dan ali
Five bottles each containing 60 ml of oral solution (300 ml) are provided in one pack.
V enem pakiranju (300 ml) je pet plastenk, vsaka vsebuje 60 ml peroralne raztopine.
Five cases were non-serious and 16 cases were serious.
Pet primerov ni bilo ocenjenih kot resni, 16 primerov pa je bilo resnih.
Five clinical studies were performed with Privigen, two included patients with PID two with patients with ITP and one with patients with CIDP.
Z zdravilom Privigen so opravili pet študij; dve pri bolnikih s PID, dve pri bolnikih z ITP in ena pri bolnikih s CIDP.
Five double­blind, randomised, controlled clinical trials were conducted to evaluate the effects of liraglutide on glycaemic control (Table 2).
Opravljenih je bilo pet dvojno slepih, randomiziranih in kontroliranih kliničnih preskušanj, v katerih so ocenjevali vpliv liraglutida na uravnavanje glikemije (preglednica 2).
Five eligible subjects were included in the study with all subjects receiving alipogene tiparvovec.
V študijo je bilo vključenih pet primernih preskušancev, od katerih so vsi prejemali alipogentiparvovek.
Five major metabolites were detected all having been shown to be pharmacologically inactive.
Zaznali so pet glavnih presnovkov, ki so farmakološko neaktivni.
Five major metabolites were detected all having been shown to be pharmacologically inactive.
Zaznali so pet glavnih presnovkov, za katere so dokazali, da niso farmakološko aktivni.
Five ml of sodium chloride 9 mg/ml (0.9%) solution for infusion or glucose 50 mg/ml (5%) solution for infusion (taken from a 100 ml bottle/bag) should be aseptically and slowly injected into each vial along the side of the inner wall.
Aseptično je treba izvleči 5 mililitrov 9 mg/ml (0,9 %) raztopine natrijevega klorida za infundiranje ali 50 mg/ml (5 %) raztopine glukoze za infundiranje (iz 100 ml steklenice/vrečke) in jih ob notranji steni viale počasi injicirati v vsako vialo.
Five of the 28 patients (18 %) [95 % CI: 6 %—37 %] treated with nelarabine achieved a complete response (bone marrow blast counts ≤ 5 %, no other evidence of disease, and full recovery of peripheral blood counts).
Popolni odziv (delež blastov v kostnem mozgu ≤ 5 %, brez drugih znakov bolezni in izboljšanje periferne krvne slike v celoti) je bil dosežen pri petih od 28 bolnikov (18 %) [95 % interval zaupanja: 6 %-37 %], ki so se zdravili z nelarabinom.
Five of the 6 patients treated with eltrombopag experienced the TEE at a platelet count > 200,000/µl
Petim od 6 bolnikov, ki so se zdravili z eltrombopagom, so se trombembolični dogodki pojavili pri številu trombocitov > 200.000/µl.
Five of the 6 patients treated with eltrombopag experienced the thrombotic complication at a platelet count > 200,000/µl and within 30 days of the last dose of eltrombopag.
Petim od 6 bolnikov, ki so se zdravili z eltrombopagom, so se trombotični zapleti pojavili pri številu trombocitov > 200.000/µl in v 30 dneh po zadnjem odmerku eltrombopaga.
Five of the pregnancies were in women weighing over 90 kg.
Do petih zanositev je prišlo pri ženskah, ki so tehtale več kot 90 kg.
Five of these NNRTI-resistant isolates were found to have K103N or a valine-to- isoleucine substitution at position 108 (V108I) in RT.
Pri petih od teh na NNRTI-je rezistentnih izolatov so našli substitucijo K103N ali substitucijo valin-v-izolevcin na položaju 108 (V108I) na RT.
Five of these NNRTI-resistant isolates were found to have K103N or a valine-to-isoleucine substitution at position 108 (V108I) in RT.
Pri petih od teh na NNRTI rezistentnih izolatov so našli substitucijo K103N ali substitucijo valin-v-izolevcin na položaju 108 (V108I) na RT.
Five of these NNRTI-resistant isolates were found to have K103N or a valine-to-isoleucine substitution at position 108 (V108I) in RT.
Pri petih od teh na NNRTI-je rezistentnih izolatov so našli substitucijo K103N ali substitucijo valin-v-izolevcin na položaju 108 (V108I) na RT.
Five of these studies were comparative: Zerene was compared with placebo (a dummy treatment) or with zolpidem or triazolam (other medicines used in insomnia).
Pet študij je bilo primerjalnih: zdravilo Zerene so primerjali s placebom (zdravilom brez zdravilne učinkovine) ali zolpidemom ali triazolamom (drugima zdraviloma za zdravljenje nespečnosti).
Five out of 37 (14%) PUP and 4 out of 23 (17%) MTP patients treated with KOGENATE Bayer developed inhibitors within 20 exposure days.
Pri 5 od 37 (14 %) predhodno nezdravljenih bolnikih in pri 4 od 23 (17 %) minimalno zdravljenih bolnikih, ki so se zdravili z zdravilom KOGENATE Bayer, so inhibitorji nastali v 20 dneh izpostavljenosti.
Five patients (0.8%) developed positive anti- tocilizumab antibodies; of these, all developed neutralizing anti-tocilizumab antibodies.
Pri petih bolnikih (0,8 %) so se pojavila protitelesa proti tocilizumabu, od teh pri vseh nevtralizacijska.
Five patients in total – all of then undergoing major knee surgery – required blood transfusion.
Transfuzijo krvi je potrebovalo skupno pet bolnikov, pri čemer so vsi imeli zahtevnejšo operacijo kolena.
Five patients with missing cirrhosis status in the SOF+RBV 24 week group were excluded from this subgroup analysis.
5 bolnikov brez statusa ciroze v skupini, ki je prejemala 24-tedensko zdravljenje s SOF + RBV, je bilo izključenih iz te analize podskupin.
Five percent (3/56) of patients without the YMDD mutant and 13 % (11/82) of patients with YMDD mutant showed worsening in liver inflammation compared to pre- treatment.
Pri 5 % (3/56) bolnikov brez YMDD mutanta in 13 % (11/82) bolnikov z YMDD mutantom so se vnetne spremembe poslabšale v primerjavi s stanjem pred zdravljenjem.
Five percent of all patients had an IRR at more than one infusion.
Pri petih odstotkih bolnikov se je infuzijska reakcija pojavila pri več kot eni infuziji.
Five single-dose containers are provided in a pouch.
V vrečki je po pet enoodmernih vsebnikov.
Five single-dose containers are then presented in a foil pouch.
Po pet enoodmernih vsebnikov je pakiranih v folijske vrečke.
Five subjects randomised to emtricitabine plus tenofovir disoproxil fumarate experienced HBsAg loss, with 2 of these 5 subjects experiencing seroconversion to anti-HBs.
Pet bolnikov, randomiziranih za emtricitabin in dizoproksiltenofovirijev fumarat, je imelo izgubo HBsAg, 2 od teh 5 bolnikov pa sta imela serološko konverzijo anti-HBs.
Five subjects were enrolled in a standard of care cohort.
Pet preiskovancev so vključili v kohorto s standardnim zdravljenjem.
Five times the recommended minimum dose applied at weekly intervals for 17 weeks was investigated in dogs aged over 6 months and tolerated with no evidence of adverse effects or undesirable clinical signs.
Pri aplikaciji petkratnega najnižjega odmerka v tedenskih intervalih,17 tednov zapored pri psih starejših od 6 mesecev ni bilo neželenih učinkov ali kliničnih znakov.
Five-week-old chickens from the vaccinated eggs were challenged with ND virus and 91% of vaccinated chickens were protected compared with no protection in the unvaccinated group.
Pet tednov stare piščance iz cepljenih jajc so v laboratoriju izpostavili virusu bolezni Newcastle in ugotovili, da je bilo 91 % cepljenih piščancev zaščitenih, medtem ko v necepljeni skupini niso ugotovili zaščite.
Five-week-old chickens from the vaccinated one-day-old chicks were challenged with ND virus and 81% of vaccinated chickens were protected compared with no protection in the unvaccinated group.
Pet tednov stare piščance iz skupine cepljenih, en dan starih piščancev so v laboratoriju izpostavili virusu bolezni Newcastle in ugotovili, da je bilo 81 % cepljenih piščancev zaščitenih, medtem ko v necepljeni skupini niso ugotovili zaščite.
fixation of the eyeballs in one position, blurred vision, eye pain, double vision abnormal heart beat, slow or fast heart rate, abnormal electrical conduction of the heart, abnormal reading (ECG) of the heart
fiksacija očesnih zrkel, zamegljen vid, bolečina v očeh, dvojni vid, motnje srčnega ritma, počasen ali hiter srčni utrip, nenormalna električna prevodnost srca, simptomi, ki povzročijo nepravilne odčitke srca (EKG),
Fixed, irrational ideas (delusions), aggression
fiksne, iracionalne ideje (blodnje), agresija;
fixed-dose
kombinacije
fixed-dose
odmerek
Fixed-time periodc
Določeno časovno obdobjec
Flange
Prirobni ca
Flank pain
bolečina ledveno
Flank pain
bolečine v ledvenem predelu
Flank pain Myalgia Muscle spasms
bolečine v ledvenem predelu mialgija mišični krči
Flare treatment
Zdravljenje izbruha bolezni
Flare up of old infections
ponovitev starih okužb
Flare was defined as:
Poslabšanje je bilo definirano kot:
Flares on treatment: Spontaneous exacerbations in chronic hepatitis B are relatively common and are characterised by transient increases in serum ALT.
Poslabšanje med zdravljenjem: Spontana poslabšanja kroničnega hepatitisa B so sorazmerno običajna, zanje pa so značilna prehodna zvišanja ALT v serumu.
Flaring up of autoimmune conditions (a disease that results from an abnormal immune response is an autoimmune disease) skin reactions remote from the application site
poslabšanje avtoimunskih obolenj (bolezen, ki je posledica nenormalnega imunskega odziva, imenujemo avtoimunska bolezen), kožne reakcije na oddaljenih mestih.
flashes of light in the eye
utrinki svetlobe v očesu
flat, pink maculae without signs of hyperkeratosis and erythema, slight palpability, with AK felt better than seen
ploščati, rožnati madeži brez znakov hiperkeratoze in eritema, rahlo se občutijo, pri aktinični keratozi so bolj otipljivi kot vidni
Flat-faced, white, round bevelled-edge tablet, embossed on one side with a “C” and on the other side with “1”.
Ploska, bela, okrogla prirezana tableta z oznako ‘C’ na eni strani in na drugi strani ‘1’.
Flat-faced, white, round bevelled-edge tablet, embossed on one side with a “C” and on the other side with “2”.
Ploska, bela, okrogla prirezana tableta z oznako ‘C’ na eni strani in na drugi strani ‘2’.
Flat-faced, white, round bevelled-edge tablet, embossed on one side with a “C” and on the other side with “4”.
Ploska, bela, okrogla prirezana tableta z oznako ‘C’ na eni strani in na drugi strani ‘4’.
Flat-faced, white, round bevelled-edge tablet, embossed on one side with a “C” and on the other side with “6”.
Ploska, bela, okrogla prirezana tableta z oznako ‘C’ na eni strani in na drugi strani ‘6’.
Flat-faced, white, round bevelled-edge tablet, embossed on one side with a “C” and on the other side with “8”.
Ploska, bela, okrogla prirezana tableta z oznako ‘C’ na eni strani in na drugi strani ‘8’.
flatulence
dispepsija
Flatulence
flatulenca
flatulence
napenjanje
Flatulence
napenjanje in vetrovi
flatulence
pustuloza (AGEP)),
flatulence
vetrovi
Flatulence
vetrovi,
Flatulence (breaking wind more often)
napenjanje (pogosti vetrovi),
flatulence (farting, feeling bloated)
napenjanje (vetrovi, občutek napihnjenosti),
flatulence (passing gas)
vetrovi (napenjanje)
Flatulence (when you break wind more often)
napenjanje (pogosti vetrovi),
Flatulence (wind)
napenjanje (vetrovi),
flatulence (wind)
vetrovi,
Flatulence (wind), haemorrhoids, bleeding from gums, bleeding from the rectum, a burning or stinging sensation in the mouth
napenjanje (vetrovi), hemoroidi, krvavitve iz dlesni, krvavitve iz danke, pekoč ali zbadajoč občutek v ustih
Flatulence,
vetrovi,
Flatulence, abdominal distension, gastro-oesophageal reflux, constipation, dry mouth, gastritis
flatulenca, napihnjen trebuh, gastroezofagealni refluks, obstipacija, suha usta, gastritis
flatulence, constipation, anorectal discomfort
flatulenca, zaprtje, anorektalno nelagodje
flatulence, constipation, indigestion, vomiting
nabiranje plinov v želodcu in črevesju, zaprtje, slaba prebava, bruhanje,
Flatulence, Dry
flatulenca, suha
Flatulence, vomiting
vetrovi, bruhanje
flatulence/passing wind
napenjanje/vetrovi,
Flatulencea
flatulencaa
flavouring containing: maltodextrin and dextrin, natural flavouring containing: maltodextrin, glycerol (E422) and propylene glycol (E1520), lemon flavouring containing: maltodextrin and alpha-tocopherol (E307)).
aroma vsebuje: maltodekstrin, dekstrin; naravna aroma vsebuje: maltodekstrin, glicerol (E422), propilenglikol (E1520); aroma limone vsebuje: maltodekstrin, alfa-tokoferol (E307).
Flea  Heartworm
glista glista
Flea Heartworm
bolha srčna glista
Flea Heartworm
glista glista
Flea larvae in the pet’s surroundings are killed after contact with a pet treated with the product.
Ličinke v okolici poginejo, ko pridejo v stik z zdravljeno živaljo.
Flea larvae Otodectes
Notoedres (pršice vrste Notoedres cati)
Flea larvae Sarcoptes
bolha ličinke garje (Sarcoptes)
Flea Otodectes
bolha ušesne garje
Flea treatment and prevention (cats and dogs)
Zdravljenje in preprečevanje infestacije z bolhami (psi in mačke)
Flea treatment and prevention (cats and dogs) Animals older than six weeks of age:
Zdravljenje in preprečevanje infestacije z bolhami (mačke in psi) Živali starejše od 6 tednov:
Flea treatment and prevention (Ctenocephalides felis)
Zdravljenje in preprečevaje bolhavosti (Ctenocephalides felis)
Fleas and ticks must attach to the host and commence feeding in order to be exposed to the active substance.
Bolhe in klopi se morajo pritrditi in začeti s hranjenjem na gostitelju, da so izpostavljeni zdravilnim učinkovinam.
Fleas and ticks must attach to the host and commence feeding in order to be exposed to the active substance.
Da pride do izpostavljenosti zdravilni učinkovini, morajo bolhe in klopi priti v stik z gostiteljem in pričeti s hranjenjem.
Fleas and ticks must attach to the host and commence feeding in order to be exposed to the active substance.
Da pride do izpostavljenosti zdravilni učinkovini, se morajo bolhe in klopi pritrditi na gostitelja in pričeti s hranjenjem.
Fleas and ticks need to start feeding on the host to become exposed to afoxolaner; therefore the risk of the transmission of vector-borne diseases cannot be excluded.
Paraziti se morajo začeti hraniti na gostitelju, da pridejo v stik z afoksolanerom , zato prenosa bolezni, ki se prenašajo s paraziti, ni mogoče izključiti.
Fleas and ticks need to start feeding on the host to become exposed to the substance afoxolaner; therefore the risk of the transmission of diseases by fleas and ticks cannot be excluded.
Paraziti se morajo začeti hraniti, da pridejo v stik z zdravilno učinkovino afoksolaner , zato prenosa bolezni, ki jih prenašajo bolhe in klopi ni mogoče povsem izključiti.
Fleas are killed by dinotefuran within 2 hours after treatment or infestation.
Bolhe dinotefuran ubije v 3 urah po zdravljneju ali okužbi.
Fleas can infest the cat’s basket, bedding and regular resting areas such as carpets and soft furnishings.
Bolhe se lahko zanesejo tudi v košaro živali, odeje ter na druga mesta, kjer živali običajno ležijo, kot so preproge in oblazinjeno pohištvo.
Fleas can infest the dog’s basket, bedding and regular resting areas such as carpets and soft furnishings.
Bolhe se lahko zanesejo tudi v košaro živali, odeje ter na druga mesta, kjer živali običajno ležijo, kot so preproge in oblazinjeno pohištvo.
Fleas from pets often infest animal’s basket, bedding and regular resting areas such as carpets and soft furnishings.
Bolhe domačih živali pogosto infestirajo košaro živali, ležišče in prostore, v katerih žival redno počiva, kot so preproge in oblazinjeno pohištvo.
Fleas from pets often infest the animal’s basket, bedding and regular resting areas such as carpets and soft furnishings, which should be treated in case of massive infestation and at the beginning of the treatment with a suitable insecticide and vacuumed regularly.
Bolhe domačih živali pogosto infestirajo košaro, ležišče in prostore, kjer žival redno počiva, kot so preproge in oblazinjena pohištva; te morate v primeru hude infestacije in ob začetku zdravljenja obdelati z ustreznim insekticidom in jih redno sesati.
Fleas from pets often infest the animal’s basket, bedding and regular resting areas such as carpets and soft furnishings.
Bolhe domačih živali pogosto infestirajo košaro živali, ležišče in prostore, v katerih žival redno počiva, kot so preproge in oblazinjeno pohištvo.
Fleas may be observed for a period of time after administration of the product due to the emergence of adult fleas from pupae already present in the environment.
Bolhe se lahko zaradi razvoja odraslih bolh iz bub, ki so že v okolju, pojavljajo še nekaj časa tudi v obdobju po dajanju zdravila.
Fleas may be observed for a period of time after administration of the veterinary medicinal product due to the emergence of adult fleas from pupae already present in the environment.
Bolhe se lahko zaradi razvoja odraslih bolh iz bub, ki so že v okolju, pojavljajo tudi še nekaj časa po dajanju zdravila.
Flebogamma DIF 100 mg/ml has a half-life of about 34-37 days.
Razpolovni čas zdravila Flebogamma DIF 100 mg/ml je od 34 do 37 dni.
Flebogamma DIF 100 mg/ml is contraindicated in children aged 0 to 2 years (see section 4.3).
Zdravilo Flebogamma DIF 100 mg/ml je kontraindicirano pri otrocih, starih od 0 do 2 let (glejte poglavje 4.3).
Flebogamma DIF 100 mg/ml solution for infusion
Flebogamma DIF 100 mg/ml raztopina za infundiranje
Flebogamma DIF 100 mg/ml solution for infusion
Flebogamma DIF 100 mg/ml raztopina za infundiranje humani polispecifični imunoglobulin (i.v.
Flebogamma DIF 50 mg/ml has a half-life of about 30-32 days.
Razpolovni čas zdravila Flebogamma DIF 50 mg/ml je od 30 do 32 dni.
Flebogamma DIF 50 mg/ml should be infused intravenously at an initial rate of 0.01 - 0.02 ml/kg/min for the first thirty minutes.
Zdravilo Flebogamma DIF 50 mg/ml infundirajte intravensko z začetno hitrostjo 0,01–0,02 ml/kg/min prvih trideset minut.
Flebogamma DIF 50 mg/ml solution for infusion
Flebogamma DIF 50 mg/ml raztopina za infundiranje
Flebogamma DIF 50 mg/ml solution for infusion
Flebogamma DIF 50 mg/ml raztopina za infundiranje humani polispecifični imunoglobulin (i.v.
Flebogamma DIF 50 mg/ml solution for infusion Human normal immunoglobulin (IVIg)
Flebogamma DIF 50 mg/ml raztopina za infundiranje humani polispecifični imunoglobulin (i.v.
Flebogamma DIF contains human normal immunoglobulin.
Zdravilo Flebogamma DIF vsebuje humani polispecifični imunoglobulin.
Flebogamma DIF contains human normal immunoglobulin.
Zdravilo Flebogamma DIF vsebuje humani polispecifični imunoglobulini.
Flebogamma DIF is given by injection into your veins (intravenous administration).
Zdravilo Flebogamma DIF se daje z injiciranjem v vene (intravenska uporaba).
Flebogamma DIF is supplied as 5 g/50 ml, 10 g/100 ml and 20 g/200 ml.
Zdravilo Flebogamma DIF je na voljo v vialah po 5 g/50 ml, 10 g/100 ml in 20 g/200 ml.
Flebogamma DIF should be infused intravenously at an initial rate of 0.01-0.02 ml/kg/min for the first thirty minutes.
Zdravilo Flebogamma DIF infundirajte intravensko z začetno hitrostjo 0,01–0,02 ml/kg/min prvih trideset minut.
flecainide and propafenone (heart medicines)
flekainid in propafenon (zdravila za srce).
Flecainide Systemic lidocaine Mexiletine Propafenone
dizopiramid flekainid sistemski lidokain meksiletin propafenon
Flecainide Systemic lidocaine Mexiletine Propafenone
dizopiramid flekainid sistemski lidokain meksilitin propafenon
Flecainide:  expected Propafenone:  expected
flekainide:  pričakovano propafenon:  pričakovano
Flesh colour cap imprinted with “R” & flesh color body imprinted with “3”
Kapa svetlo rjave barve z natisnjenim napisom »R« in telo svetlo rjave barve z natisnjenim napisom »3«.
Flexibility in dosing time
Prilagodljiv čas uporabe
Flexibility in dosing time
Prilagodljivost časa odmerjanja
Flexibility in time of administration
Prilagodljivost časa uporabe
Flexible quit date between weeks 1 and 5
Poljubno izbran datum opustitve kajenja v obdobju od 1. do 5. tedna
Flexicam
pakiranja
Flexicam 5 mg/ml solution for injection for dogs and cats Meloxicam
Flexicam 5 mg/ml, raztopina za injiciranje za pse in mačke Meloksikam
Flexicam is efficacious in alleviating the inflammation and pain in both acute and chronic musculo- skeletal disorders and reducing the post operative pain following orthopaedic and soft tissue surgery in dogs and in reducing the post-operative pain after ovariohysterectomy and minor soft tissue surgery in cats.
Zdravilo Flexicam je učinkovito pri umirjanju vnetja in lajšanju bolečine pri akutnih in kroničnih mišično-skeletnih obolenjih ter lajšanju pooperativne bolečine po ortopedskih operacijah in operacijah mehkega tkiva pri psih ter lajšanju pooperativne bolečine po ovariohisterektomiji in manjših operacijah mehkega tkiva pri mačkah.
Flexicam should also not be used in animals suffering from gastrointestinal or hemorrhagic disorders and impaired renal or hepatic function, animals with known hypersensitivity to NSAIDs, and animals less than 6 weeks of age or in cats of less than 2 kg.
Zdravilo Flexicam se ne sme uporabljati pri živalih z obolenji prebavil ali hemoragičnimi obolenji ter pri motnjah jetrne ali ledvične funkcije, živalih z ugotovljeno preobčutljivostjo na nesteroidna protivnetna zdravila ter živalih, mlajših od 6 tednov, ali mačkah, lažjih od 2 kg.
FlexPen delivers 1–60 units in increments of 1 unit.
Injekcijski peresnik FlexPen omogoča aplikacijo od 1 do 60 enot v korakih po 1 enoto.